Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
MENLO PARK, Calif., April 18, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2017 Financial Results on Wednesday, April 26, 2017, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: April 26, 2017
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Audience Passcode: 1033-2877
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
